Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with adjuvant radiotherapy or chemoradiotherapy for resectable oral cancer at risk of recurrence
ChiCTR2100050906Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in mouth cancer (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Three-year disease-free survival rate. Started Aug 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
mouth cancer
Beyond the preview
Go deeper on ChiCTR2100050906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050906.